Table 3

Change in medical outcomes at posttreatment from baseline

OutcomeTreatment, least square mean (SE)1P value compared with UC
CBT (N = 24)CBT+EXER (N = 25)EXER (N = 30)UC (N = 28)CBTCBT+EXEREXER
HbA1c2
 All subjects0.06 (0.13)−0.17 (0.13)−0.03 (0.13)0.20 (0.13)0.3790.0160.132
 Baseline value ≥7%0.06 (0.18)−0.74 (0.21)−0.07 (0.17)0.31 (0.18)0.254<0.00010.074
  N = 60(N = 16)(N = 10)(N = 18)(N = 16)
Fasting glucose10.61 (10.91)−23.18 (10.46)−4.70 (10.85)1.65 (10.65)0.5620.0910.653
Total cholesterol−6.40 (6.26)−4.15 (5.92)−4.95 (6.21)12.15 (6.11)0.0390.0520.037
HDL−0.47 (1.40)1.19 (1.35)−0.97 (1.41)0.35 (1.37)0.6770.6540.471
LDL−6.24 (4.85)−2.09 (4.59)0.07 (4.82)1.83 (4.73)0.2410.5410.780
Triglycerides3−1.58 (13.61)−20.09 (12.88)−8.57 (13.46)10.43 (13.76)0.5380.0990.293
BMI0.60 (0.48)0.04 (0.47)0.14 (0.48)0.91 (0.47)0.6460.1830.218
6MWT distance (feet)−6.16 (33.03)0.74 (31.48)65.60 (32.60)23.68 (33.26)0.5290.6050.329
  • P values reaching statistical significance appear in boldface type.

  • 1Treatment group comparisons for non-HbA1c outcomes were adjusted for baseline education status and baseline outcome values.

  • 2Treatment group comparisons for HbA1c were adjusted for baseline education status, baseline outcome values, and change in antidiabetic medication (0 if no change, 1 if an increase, and −1 if a decrease) at postassessment.

  • 3Outliers for N = 2 observations were removed for this value.